BML details 9.9% PMV Pharmaceuticals (PMVP) stake in Schedule 13G/A

Rhea-AI Filing Summary

BML Investment Partners, L.P. filed an amended Schedule 13G reporting its ownership in PMV Pharmaceuticals, Inc.. The fund reports beneficial ownership of 5,292,000 shares of common stock, representing 9.9% of the class as of the event date.

BML has shared voting and dispositive power over all 5,292,000 shares and no sole voting or dispositive power. The filing notes that the securities are not held for the purpose of changing or influencing control of PMV Pharmaceuticals. Braden M. Leonard is deemed an indirect owner through BML Capital Management, LLC, the general partner.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

PMV Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value per share

(Title of Class of Securities)

69353Y103

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 69353Y103

1

Names of Reporting Persons

BML Investment Partners, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,292,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,292,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,292,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PMV Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 400 Alexander Park Drive, Suite 301, Princeton, New Jersey, 08540
Item 2.
(a)	Name of person filing: BML Investment Partners, L.P.
(b)	Address or principal business office or, if none, residence: 65 E Cedar, Suite 2 Zionsville, IN 46077
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock, $0.00001 par value per share
(e)	CUSIP No.: 69353Y103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5292000
(b)	Percent of class: 9.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 5292000
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 5292000
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BML Investment Partners, L.P.

Signature:	Braden M Leonard
Name/Title:	BML Capital Management, LLC its General Partner By: Braden M Leonard, its Managing Member
Date:	02/09/2026

Comments accompanying signature: BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.

FAQ

What stake in PMV Pharmaceuticals (PMVP) does BML Investment Partners report?

BML Investment Partners, L.P. reports beneficial ownership of 5,292,000 PMV Pharmaceuticals shares. This position represents 9.9% of the company’s common stock. All of these shares are held with shared voting and shared dispositive power, according to the Schedule 13G/A filing.

What type of SEC filing did BML submit for PMV Pharmaceuticals (PMVP)?

BML Investment Partners filed an amended Schedule 13G/A for PMV Pharmaceuticals. This schedule is used to report ownership by investors who classify their holdings as passive, rather than for the purpose of changing or influencing control of the issuer.

Does BML Investment Partners seek to influence control of PMV Pharmaceuticals (PMVP)?

The filer certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of PMV Pharmaceuticals. The filing also states they are not held in connection with any transaction having that purpose or effect, subject to the noted nomination exception.

What voting and dispositive powers does BML have over PMV Pharmaceuticals (PMVP) shares?

BML Investment Partners reports 0 shares with sole voting or dispositive power and 5,292,000 shares with shared voting and shared dispositive power. This means control over voting and disposition of the reported shares is shared, not held solely by the reporting person.

Who signs the PMV Pharmaceuticals (PMVP) Schedule 13G/A for BML Investment Partners?

The Schedule 13G/A is signed by Braden M. Leonard on behalf of BML Capital Management, LLC, the general partner of BML Investment Partners, L.P. The filing states Leonard is deemed an indirect owner of the shares held directly by the partnership.

What percentage threshold does BML Investment Partners exceed in PMV Pharmaceuticals (PMVP)?

BML Investment Partners reports owning 9.9% of the outstanding common stock of PMV Pharmaceuticals. This exceeds the 5% reporting threshold that triggers a beneficial ownership disclosure requirement under U.S. securities regulations for Schedule 13D or 13G filings.

Do the reporting persons claim to be a group in the PMV Pharmaceuticals (PMVP) filing?

The comments clarify that although Braden M. Leonard is deemed an indirect owner of shares held by BML Investment Partners, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) under the Exchange Act.